All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 93 points (0.5%) at 17,674 as of Wednesday, Oct. 28, 2015, 12:55 PM ET. The NYSE advances/declines ratio sits at 2,445 issues advancing vs. 542 declining with 141 unchanged.

The Health Care sector currently sits up 2.1% versus the S&P 500, which is up 0.7%. On the negative front, top decliners within the sector include Gilead ( GILD), down 2.7%, CVS Health ( CVS), down 1.8% and Regeneron Pharmaceuticals ( REGN), down 0.8%. Top gainers within the sector include Boston Scientific ( BSX), up 7.8%, GlaxoSmithKline ( GSK), up 4.3%, Teva Pharmaceutical Industries ( TEVA), up 4.3%, Express Scripts ( ESRX), up 2.9% and Merck ( MRK), up 2.5%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. IDEXX Laboratories ( IDXX) is one of the companies pushing the Health Care sector lower today. As of noon trading, IDEXX Laboratories is down $9.10 (-11.9%) to $67.64 on heavy volume. Thus far, 2.4 million shares of IDEXX Laboratories exchanged hands as compared to its average daily volume of 633,600 shares. The stock has ranged in price between $65.03-$69.10 after having opened the day at $68.75 as compared to the previous trading day's close of $76.74.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. IDEXX Laboratories has a market cap of $7.0 billion and is part of the drugs industry. Shares are up 3.5% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts that rate IDEXX Laboratories a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates IDEXX Laboratories as a hold. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share and revenue growth. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and weak operating cash flow. Get the full IDEXX Laboratories Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading, Vertex Pharmaceuticals ( VRTX) is down $2.31 (-1.9%) to $118.70 on heavy volume. Thus far, 1.9 million shares of Vertex Pharmaceuticals exchanged hands as compared to its average daily volume of 2.0 million shares. The stock has ranged in price between $117.86-$121.87 after having opened the day at $120.40 as compared to the previous trading day's close of $121.01.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Vertex Pharmaceuticals Incorporated engages in discovering, developing, manufacturing, and commercializing small molecule drugs for patients with serious diseases in specialty markets. Vertex Pharmaceuticals has a market cap of $28.1 billion and is part of the drugs industry. Shares are up 1.9% year-to-date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Vertex Pharmaceuticals a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Vertex Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Vertex Pharmaceuticals Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading, Anthem ( ANTM) is down $1.87 (-1.3%) to $142.82 on heavy volume. Thus far, 3.4 million shares of Anthem exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $134.74-$144.98 after having opened the day at $141.00 as compared to the previous trading day's close of $144.69.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Anthem, Inc., through its subsidiaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other. Anthem has a market cap of $37.1 billion and is part of the health services industry. Shares are up 15.1% year-to-date as of the close of trading on Tuesday. Currently there are 9 analysts that rate Anthem a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Anthem as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. We feel its strengths outweigh the fact that the company shows low profit margins. Get the full Anthem Ratings Report now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).